A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy.

R.J. Van Geest, S.Y. Lesnik-Oberstein, H.S. Tan, M. Mura, R. Goldschmeding, C.J. Van Noorden, I. Klaassen, R.O. Schlingemann

Research output: Contribution to journal/periodicalArticleScientificpeer-review

Original languageEnglish
Pages (from-to)587-590
JournalBritish Journal of Ophthalmology
Publication statusPublished - 2012

Cite this